Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares China Large-Cap ETF (FXI) vs Mesoblast Limited (MESO) Price & Performance

iShares China Large-Cap ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

iShares China Large-Cap ETF vs Mesoblast Limited — how do they compare? iShares China Large-Cap ETF trades at $35.21, while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.

FXIMESO
52-Week High
$41.75$20.96
52-Week Low
$31.59$12.88
Market Cap
$2.21B
Sector
Technology
Enterprise Value
$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares China Large-Cap ETF

FXI, the iShares China Large-Cap ETF, trades at $35.26, down 3.37% on the day, reflecting recent pressure on Chinese equities. Technical indicators show a bullish moving average signal but neutral oscillators, with key resistance at $37. Recent news highlights China's export strength and state-backed economic support, though geopolitical tensions and U.S. restrictions pose headwinds. The ETF offers exposure to China's financial and industrial giants, with a dividend scheduled for June 2026.

The outlook for FXI is mixed; bullish technical trends and China's policy support may drive gains, but risks include U.S.-China tensions and domestic economic volatility. Investors should weigh diversification benefits against regulatory and macroeconomic uncertainties, with Wall Street sentiment cautious amid fluctuating analyst views.

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Returns comparison

Trailing returns across standard periods

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO